These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

554 related items for PubMed ID: 20542064

  • 1. Locomotor response to L-DOPA in reserpine-treated rats following central inhibition of aromatic L-amino acid decarboxylase: further evidence for non-dopaminergic actions of L-DOPA and its metabolites.
    Alachkar A, Brotchie JM, Jones OT.
    Neurosci Res; 2010 Sep; 68(1):44-50. PubMed ID: 20542064
    [Abstract] [Full Text] [Related]

  • 2. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
    Johnston TH, Lee J, Gomez-Ramirez J, Fox SH, Brotchie JM.
    Exp Neurol; 2005 Feb; 191(2):243-50. PubMed ID: 15649479
    [Abstract] [Full Text] [Related]

  • 3. L-3,4-dihydroxyphenylalanine-induced c-Fos expression in the CNS under inhibition of central aromatic L-amino acid decarboxylase.
    Shimamura M, Shimizu M, Yagami T, Funabashi T, Kimura F, Kuroiwa Y, Misu Y, Goshima Y.
    Neuropharmacology; 2006 Jun; 50(8):909-16. PubMed ID: 16504219
    [Abstract] [Full Text] [Related]

  • 4. Dual effects of L-3,4-dihydroxyphenylalanine on aromatic L-amino acid decarboxylase, dopamine release and motor stimulation in the reserpine-treated rat: evidence that behaviour is dopamine independent.
    Fisher A, Biggs CS, Eradiri O, Starr MS.
    Neuroscience; 2000 Jun; 95(1):97-111. PubMed ID: 10619466
    [Abstract] [Full Text] [Related]

  • 5. Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease.
    Segovia G, Mora F, Crossman AR, Brotchie JM.
    Mov Disord; 2003 Feb; 18(2):138-49. PubMed ID: 12539206
    [Abstract] [Full Text] [Related]

  • 6. Actions at sites other than D(3) receptors mediate the effects of BP897 on l-DOPA-induced hyperactivity in monoamine-depleted rats.
    Visanji NP, Millan MJ, Brotchie JM.
    Exp Neurol; 2006 Nov; 202(1):85-92. PubMed ID: 16814282
    [Abstract] [Full Text] [Related]

  • 7. The antiparkinsonian drug budipine stimulates the activity of aromatic L-amino acid decarboxylase and enhances L-DOPA-induced dopamine release in rat substantia nigra.
    Biggs CS, Fisher A, Starr MS.
    Synapse; 1998 Nov; 30(3):309-17. PubMed ID: 9776134
    [Abstract] [Full Text] [Related]

  • 8. Intrastriatal inhibition of aromatic amino acid decarboxylase prevents l-DOPA-induced dyskinesia: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine lesioned rats.
    Buck K, Ferger B.
    Neurobiol Dis; 2008 Feb; 29(2):210-20. PubMed ID: 17920284
    [Abstract] [Full Text] [Related]

  • 9. A role for vanilloid receptor 1 (TRPV1) and endocannabinnoid signalling in the regulation of spontaneous and L-DOPA induced locomotion in normal and reserpine-treated rats.
    Lee J, Di Marzo V, Brotchie JM.
    Neuropharmacology; 2006 Sep; 51(3):557-65. PubMed ID: 16806299
    [Abstract] [Full Text] [Related]

  • 10. L-DOPA reverses the hypokinetic behaviour and rigidity in rotenone-treated rats.
    Alam M, Schmidt WJ.
    Behav Brain Res; 2004 Aug 31; 153(2):439-46. PubMed ID: 15265640
    [Abstract] [Full Text] [Related]

  • 11. In vivo antagonism of the behavioral responses to L-3-,4-dihydroxyphenylalanine by L-3-,4-dihydroxyphenylalanine cyclohexyl ester in conscious rats.
    Matsushita N, Misu Y, Goshima Y.
    Eur J Pharmacol; 2009 Mar 01; 605(1-3):109-13. PubMed ID: 19168057
    [Abstract] [Full Text] [Related]

  • 12. Increased neostriatal dopamine activity after intraperitoneal or intranasal administration of L-DOPA: on the role of benserazide pretreatment.
    Silva MA, Mattern C, Häcker R, Tomaz C, Huston JP, Schwarting RK.
    Synapse; 1997 Dec 01; 27(4):294-302. PubMed ID: 9372552
    [Abstract] [Full Text] [Related]

  • 13. Interactions between a novel cholinergic ion channel agonist, SIB-1765F and L-DOPA in the reserpine model of Parkinson's disease in rats.
    Menzaghi F, Whelan KT, Risbrough VB, Rao TS, Lloyd GK.
    J Pharmacol Exp Ther; 1997 Jan 01; 280(1):393-401. PubMed ID: 8996220
    [Abstract] [Full Text] [Related]

  • 14. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Henry B, Crossman AR, Brotchie JM.
    Exp Neurol; 1998 Jun 01; 151(2):334-42. PubMed ID: 9628768
    [Abstract] [Full Text] [Related]

  • 15. The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy.
    Eskow KL, Gupta V, Alam S, Park JY, Bishop C.
    Pharmacol Biochem Behav; 2007 Jun 01; 87(3):306-14. PubMed ID: 17553556
    [Abstract] [Full Text] [Related]

  • 16. Benserazide dosing regimen affects the response to L-3,4-dihydroxyphenylalanine in the 6-hydroxydopamine-lesioned rat.
    Tayarani-Binazir KA, Jackson MJ, Strang I, Jairaj M, Rose S, Jenner P.
    Behav Pharmacol; 2012 Apr 01; 23(2):126-33. PubMed ID: 22236652
    [Abstract] [Full Text] [Related]

  • 17. The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTP-treated common marmoset.
    Tayarani-Binazir KA, Jackson MJ, Fisher R, Zoubiane G, Rose S, Jenner P.
    Eur J Pharmacol; 2010 Jun 10; 635(1-3):109-16. PubMed ID: 20303948
    [Abstract] [Full Text] [Related]

  • 18. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
    Henry B, Crossman AR, Brotchie JM.
    Exp Neurol; 1999 Feb 10; 155(2):204-20. PubMed ID: 10072296
    [Abstract] [Full Text] [Related]

  • 19. Vesicular monoamine transporter-2 and aromatic L-amino acid decarboxylase gene therapy prevents development of motor complications in parkinsonian rats after chronic intermittent L-3,4-dihydroxyphenylalanine administration.
    Lee WY, Lee EA, Jeon MY, Kang HY, Park YG.
    Exp Neurol; 2006 Jan 10; 197(1):215-24. PubMed ID: 16269145
    [Abstract] [Full Text] [Related]

  • 20. Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats.
    Sánchez-Pernaute R, Harvey-White J, Cunningham J, Bankiewicz KS.
    Mol Ther; 2001 Oct 10; 4(4):324-30. PubMed ID: 11592835
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.